Research ExplorerPublicationsMolecular response patterns in relapsed/refractory AML patie...

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy

Standard

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy. / Klement, Piroska; Fiedler, Walter; Gabdoulline, Razif; Dallmann, Louisa-Kristin; Wienecke, Clara Philine; Schiller, Johannes; Kandziora, Christian; Teich, Katrin; Heida, Bennett; Büttner, Konstantin; Brandes, Maximilian; Funke, Carolin; Wichmann, Martin; Othman, Basem; Chromik, Joerg; Amberg, Stefanie; Kebenko, Maxim; Schlipfenbacher, Vera; Wilke, Anne Christine; Modemann, Franziska; Janning, Melanie; Serve, Hubert; Bokemeyer, Carsten; Theile, Susann; Deppermann, Ute; Kranich, Anne L; Ganser, Arnold; Thol, Felicitas; Heuser, Michael.

In: ANN HEMATOL, Vol. 102, No. 2, 02.2023, p. 323-328.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Klement, P, Fiedler, W, Gabdoulline, R, Dallmann, L-K, Wienecke, CP, Schiller, J, Kandziora, C, Teich, K, Heida, B, Büttner, K, Brandes, M, Funke, C, Wichmann, M, Othman, B, Chromik, J, Amberg, S, Kebenko, M, Schlipfenbacher, V, Wilke, AC, Modemann, F, Janning, M, Serve, H, Bokemeyer, C, Theile, S, Deppermann, U, Kranich, AL, Ganser, A, Thol, F & Heuser, M 2023, 'Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy', ANN HEMATOL, vol. 102, no. 2, pp. 323-328. https://doi.org/10.1007/s00277-022-05075-4

APA

Klement, P., Fiedler, W., Gabdoulline, R., Dallmann, L-K., Wienecke, C. P., Schiller, J., Kandziora, C., Teich, K., Heida, B., Büttner, K., Brandes, M., Funke, C., Wichmann, M., Othman, B., Chromik, J., Amberg, S., Kebenko, M., Schlipfenbacher, V., Wilke, A. C., ... Heuser, M. (2023). Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy. ANN HEMATOL, 102(2), 323-328. https://doi.org/10.1007/s00277-022-05075-4

Vancouver

Klement P, Fiedler W, Gabdoulline R, Dallmann L-K, Wienecke CP, Schiller J et al. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy. ANN HEMATOL. 2023 Feb;102(2):323-328. https://doi.org/10.1007/s00277-022-05075-4

Bibtex

@article{63824d59bd524b5f89f73422e34cda5d,
title = "Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy",
abstract = "Relapse in patients with acute myeloid leukemia (AML) is common and is associated with a dismal prognosis. Treatment options are limited and the understanding of molecular response patterns is still challenging. We analyzed the clonal response patterns of 15 patients with relapsed/refractory AML treated with selinexor in a phase II trial (SAIL). DNA was analyzed at three time points and showed a decline of mutated alleles in FLT3, SF3B1, and TP53 under SAIL treatment. Overall survival (OS) was similar between patients with declining versus persisting clones. We show an interesting long-term course of a patient who relapsed after allogeneic stem cell transplantation (alloHCT) with SF3B1- and SRSF2-mutated AML and received selinexor as maintenance treatment for 4 years. Measurable residual disease (MRD) remained detectable for 2 weeks after donor lymphocyte infusion (DLI) in this patient and then remained negative under selinexor maintenance treatment. Selinexor was tolerated well and was stopped after 4 years of SAIL treatment. We present an exploratory study and identify subclonal patterns of patients treated with selinexor.",
author = "Piroska Klement and Walter Fiedler and Razif Gabdoulline and Louisa-Kristin Dallmann and Wienecke, {Clara Philine} and Johannes Schiller and Christian Kandziora and Katrin Teich and Bennett Heida and Konstantin B{\"u}ttner and Maximilian Brandes and Carolin Funke and Martin Wichmann and Basem Othman and Joerg Chromik and Stefanie Amberg and Maxim Kebenko and Vera Schlipfenbacher and Wilke, {Anne Christine} and Franziska Modemann and Melanie Janning and Hubert Serve and Carsten Bokemeyer and Susann Theile and Ute Deppermann and Kranich, {Anne L} and Arnold Ganser and Felicitas Thol and Michael Heuser",
note = "{\textcopyright} 2022. The Author(s).",
year = "2023",
month = feb,
doi = "10.1007/s00277-022-05075-4",
language = "English",
volume = "102",
pages = "323--328",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy

AU - Klement, Piroska

AU - Fiedler, Walter

AU - Gabdoulline, Razif

AU - Dallmann, Louisa-Kristin

AU - Wienecke, Clara Philine

AU - Schiller, Johannes

AU - Kandziora, Christian

AU - Teich, Katrin

AU - Heida, Bennett

AU - Büttner, Konstantin

AU - Brandes, Maximilian

AU - Funke, Carolin

AU - Wichmann, Martin

AU - Othman, Basem

AU - Chromik, Joerg

AU - Amberg, Stefanie

AU - Kebenko, Maxim

AU - Schlipfenbacher, Vera

AU - Wilke, Anne Christine

AU - Modemann, Franziska

AU - Janning, Melanie

AU - Serve, Hubert

AU - Bokemeyer, Carsten

AU - Theile, Susann

AU - Deppermann, Ute

AU - Kranich, Anne L

AU - Ganser, Arnold

AU - Thol, Felicitas

AU - Heuser, Michael

N1 - © 2022. The Author(s).

PY - 2023/2

Y1 - 2023/2

N2 - Relapse in patients with acute myeloid leukemia (AML) is common and is associated with a dismal prognosis. Treatment options are limited and the understanding of molecular response patterns is still challenging. We analyzed the clonal response patterns of 15 patients with relapsed/refractory AML treated with selinexor in a phase II trial (SAIL). DNA was analyzed at three time points and showed a decline of mutated alleles in FLT3, SF3B1, and TP53 under SAIL treatment. Overall survival (OS) was similar between patients with declining versus persisting clones. We show an interesting long-term course of a patient who relapsed after allogeneic stem cell transplantation (alloHCT) with SF3B1- and SRSF2-mutated AML and received selinexor as maintenance treatment for 4 years. Measurable residual disease (MRD) remained detectable for 2 weeks after donor lymphocyte infusion (DLI) in this patient and then remained negative under selinexor maintenance treatment. Selinexor was tolerated well and was stopped after 4 years of SAIL treatment. We present an exploratory study and identify subclonal patterns of patients treated with selinexor.

AB - Relapse in patients with acute myeloid leukemia (AML) is common and is associated with a dismal prognosis. Treatment options are limited and the understanding of molecular response patterns is still challenging. We analyzed the clonal response patterns of 15 patients with relapsed/refractory AML treated with selinexor in a phase II trial (SAIL). DNA was analyzed at three time points and showed a decline of mutated alleles in FLT3, SF3B1, and TP53 under SAIL treatment. Overall survival (OS) was similar between patients with declining versus persisting clones. We show an interesting long-term course of a patient who relapsed after allogeneic stem cell transplantation (alloHCT) with SF3B1- and SRSF2-mutated AML and received selinexor as maintenance treatment for 4 years. Measurable residual disease (MRD) remained detectable for 2 weeks after donor lymphocyte infusion (DLI) in this patient and then remained negative under selinexor maintenance treatment. Selinexor was tolerated well and was stopped after 4 years of SAIL treatment. We present an exploratory study and identify subclonal patterns of patients treated with selinexor.

U2 - 10.1007/s00277-022-05075-4

DO - 10.1007/s00277-022-05075-4

M3 - SCORING: Journal article

C2 - 36576532

VL - 102

SP - 323

EP - 328

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 2

ER -